Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines

doi:10.19803/j.1672-8629.2021.05.02

Abstract

Abstract: Objective To provide reference for the construction of pharmacovigilance systems of traditional Chinese medicine(TCM) and natural medicines by analyzing the development of pharmacovigilance of TCM and natural medicines. Methods Domestic and foreign literature was searched. Laws, regulations and guidelines related to TCM and natural medicines in some countries and regions were retrieved, the official websites of drug regulatory agencies were browsed, and pharmacovigilance regulatory agencies, related responsibilities, and regulatory content of TCM and natural medicines in various countries and regions were analyzed. Results Pharmacovigilance of TCM and natural medicines was specified in the pharmacovigilance system in many countries and regions. The European Union, India and other countries had established related regulatory agencies and worked out specific regulatory documents for TCM and natural medicines, but related pharmacovigilance systems were still under construction. Conclusion The pharmacovigilance of TCM and natural medicines has become an important part of pharmacovigilance in various countries and regions. The pharmacovigilance system of TCM and natural medicines in China is relatively complete compared with other countries and regions. China should keep up with the development of pharmacovigilance in various countries to motivate sustained research on pharmacovigilance of TCM and natural medicines and boost the development of global pharmacovigilance systems of TCM and natural medicines.

Key words: international, pharmacovigilance, European, American, natural medicines, United Kingdom, Oceania, Asian, traditional Chinese medicine (TCM)

CLC Number:

R28R944.1

WU Hao, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng. Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 406-410.

References

[1] MHRA.Illegal herbal remedies containing aristolochia:vigilance needed[EB/OL].(2014-12-11)[2021-02-20].https://www.gov.uk/drug-safety-update-illegal-herbal-remedies-containing-aristolochia-vigilance-needed.
[2] TGA.Australian Adverse Drug Reactions Bulletin,Vol 18,No 1[EB/OL].(1999-02)[2021-02-20].https://www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-18-no-1.
[3] EMA.Committee on Herbal Medicinal Products (HMPC)[EB/OL].(2004-09)[2021-02-20].https://www.ema.europa.eu/en/committees/committee-herbal-medicinal-products-hmpc.
[4] EMA.Medicines[EB/OL].[2021-02-20].https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Herbal.
[5] EMA.Good Pharmacovigilance Practices[EB/OL].(2012-07-26)[2021-02-20].https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=GVP.
[6] EMA.European medicines agency finalises first set of guidelines on good pharmacovigilance practices[EB/OL].(2012-06-25)[2021-02-20].https://www.ema.europa.eu/en/news/european-medicines-agency-finalises-first-set-guidelines-good-pharmacovigilance-practices.
[7] Zhou F.Research on the British traditional herbal medicine management legal system and the British registration strategy of Chinese medicines[J].Global Traditional Chinese Medicine(环球中医药),2014,7(11):851-855.
[8] MHRA.Herbal medicines regulation:Licensed herbal medicines[EB/OL].[2021-2-20].http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicinesregulation/Licensedherbal-medicines/index.htm.
[9] MHRA.Banned and restricted herbal ingredients[EB/OL].(2014-12-18)[2021-2-20].https://www.gov.uk/government/publications/list-of-banned-or-restricted-herbal-ingredients-for-medicinal-use-banned-and-restricted-herbal-ingredients.
[10] FDA.Dietary Supplement Products &Ingredients[EB/OL].(2020-10-13)[2021-2-20].https://www.fda.gov/food/dietary-supplements/dietary-supplement-products-ingredients.
[11] FDA.Drug safety oversight board[EB/OL].[2021-02-20].https://www.fda.gov/about-fda-center-drug-evaluation-and-research-cder-drug-safety-oversight-board.
[12] FDA.Recalls,market withdrawals,&safety alerts[EB/OL].[2021-02-20].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts.
[13] FDA.Alerts,advisories &safety information[EB/OL].(2001-04)[2021-02-20].https://www.fda.gov/food/recalls-outbreaks-emergencies-alerts-advisories-safety-information.
[14] FDA.Pharmacy compounding advisory committee meeting 3-16[EB/OL].(2016-03)[2021-02-20].https://search.usa.gov/search?query=Anthraquinone&affiliate=fda1.
[15] FDA.Current good manufacturing practice (CGMP) regulations[EB/OL].(2020-09-21)[2021-02-20].https://www.fda.gov/drugs/pharmaceutical-quality-resources-current-good-manufacturing-practice-cgmp-regulations.
[16] TGA.Complementary medicines[EB/OL].(2020-05-20)[2021-02-20].https://www.tga.gov.au/complementary-medicines.
[17] TGA.Complementary and OTC medicines regulatory and technical consultative forum (ComTech)[EB/OL].(2021-01-08)[2021-02-20].https://www.tga.gov.au/committee/complementary-and-otc-medicines-regulatory-and-technical-consultative-forum-comtech.
[18] Wang H,Zhu Y.Application status of classical prescription in traditional Chinese medicine and Japanese Kampo medicine[J].Chinese Traditional and Herbal Drugs(中草药),2019,50(15):3714-3719.
[19] Xiao YY,Yang ZB.Enlightenment from the development of kampo medicine in japan[J].Chinese Journal of Dermatovenerology of Integrated Traditional and Western Medicine.(中国中西医结合皮肤性病学杂志),2018,17(6):554-558.
[20] Information system on safety and effectiveness for health foods.Designated ingredients,etc[EB/OL].(2020-06-01)[2021-02-20].https://hfnet.nibiohn.go.jp-contents-detail4291.html.
[21] Ministry of Health and Family Welfare.Departments of Health and Family Welfare[EB/OL].[2021-02-20].https://main.mohfw.gov.in/organisation/Departments-of-Health-and-Family-Welfare.
[22] Lin ZJ,Zhang XM,Zhang B,et al.General introduction and practice of pharmacovigilance system of Indian traditional medicine[J].Practical Pharmacy and Clinical Remedies(实用药物与临床),2018,21(3):354-358.
[23] HSA.Regulatory overview of traditional medicines[EB/OL].(2020-09-10)[2021-02-20].https://www.hsa.gov.sg/traditional-medicines-regulatory-overview-of-traditional-medicines.
[24] HSA.Traditional medicinal materials:understand the requirements for the import and sale of traditional medicinal materials in Singapore[EB/OL].(2019-10-10)[2021-02-20].https://www.hsa.gov.sg/traditional-medicines/traditional-medicinal-materials.
[25] HSA.Report adverse events[EB/OL].[2021-02-20].https://www.hsa.gov.sg/traditional-medicines/report-adverse-events.
[26] MOH.Medicines Act[EB/OL].(1987-03-30)[2021-02-20].https://sso.agc.gov.sg/Act-MA1975#pr8-.
[27] MFDS.Pharmaceutical Affairs Act[EB/OL].(2016-05-29)[2021-02-20].https://www.mfds.go.kr/eng/brd/m_18-view.do?seq=71344&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3.
[28] Ministry of Food and Drug Safety[EB/OL].[2021-2-20].https://www.mfds.go.kr/eng/wpge/m_47-de011033l001.do.
[29] MFDS.National institute of food and drug safety evaluation[EB/OL][2021-02-20].https://www.mfds.go.kr/eng/wpge-m_48/de011033l002.do.
[30] MFDS.Herbal medicine management team,herbal medicine evaluation team[EB/OL][2021-02-20].https://www.mfds.go.kr/eng/wpge/m_43/de011030l001.do.